Livazo, 4 mg 28 pcs.

Pitavastatin competitively inhibits HMG-CoA reductase, limiting the rate of action of the enzyme in cholesterol biosynthesis, inhibits the synthesis of cholesterol (Chs) in the liver. As a consequence, LDL receptor expression in the liver is increased, contributing to the uptake of circulating LDL in the blood, lowering total Chs and LDL cholesterol (Chs-LDL) in the blood. Its persistent inhibition of hepatic Chs synthesis reduces LDL secretion into the blood, lowering plasma triglyceride levels.

Indications

Primary hypercholesterolemia, including heterozygous familial hypercholesterolemia (Fredrickson type IIa hyperlipidemia) or mixed hypercholesterolemia (Fredrickson type IIb hyperlipidemia), hypertriglyceridemia (Fredrickson type IV hyperlipidemia) as an adjunct to diet, when diet and other non-medicinal treatments (e.g., exercise, weight loss) are insufficient.

Active ingredient

Pitavastatin

How to take, the dosage

Orally, the tablets should be swallowed whole.

Interaction

Cyclosporine: A 4.6-fold increase in the AUC of pitavastatin was observed when a single dose of cyclosporine was administered simultaneously with Livazo in equilibrium. Livazo is contraindicated in patients treated with cyclosporine.

Contraindications

Severe hepatic impairment (more than 9 points on the Child-Pugh scale) or Child-Pugh class C, liver disease and active phase, including a persistent increase in serum liver transaminase activity (more than 3 times that of HGH);

Side effects

Frequency is defined as: very frequently (≥1/10), frequently (≥1/100 to < 1/10), infrequently (≥1/1000 to < 1/100), rarely (≥1/10 000 to < 1/1000), very rarely (< 1/10 000) and unknown.

Overdose

An overdose may increase the symptoms of adverse reactions.